Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.

Key PointsSubstantial revenue from its flagship drug Casgevy should be right around the corner.

阅读完整 Veytics 简报

我们公开展示核心要点。创建免费账户后可继续阅读全文、保存、讨论，并结合市场和 OSINT 背景分析。